Patents Assigned to Hoffman
  • Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection
    Patent number: 9949966
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: April 24, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Xingchun Han, Hassan Javanbakht, Min Jiang, Chungen Liang, Jianping Wang, Yongguang Wang, Zhanguo Wang, Robert James Weikert, Song Yang, Chengang Zhou
  • Dual targeting
    Patent number: 9944719
    Abstract: The present invention relates to antibody-based dual targeting molecules, and to methods for generating such dual targeting molecules, including a library-based approach.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: April 17, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Roland Beckmann, Kristian Jensen
  • Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection
    Patent number: 9920049
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X and Y are as described in the description and in the claims, as well as or pharmaceutically acceptable salts, or enantiomers, or diastereomers thereof. The invention also contains compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: March 20, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Song Yang, Xingchun Han, Zhanguo Wang
  • Pyridazones and triazinones for treatment and prophylaxis of hepatitis B virus infection
    Patent number: 9902701
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, X and a are as described in the description and in the claims, as well as or pharmaceutically acceptable salts thereof. The invention also contains compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: February 27, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Song Yang, Chungen Liang, Jianping Wang, Song Pan
  • Bispecific antibodies comprising a disulfide stabilized-Fv fragment
    Patent number: 9879095
    Abstract: The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: January 30, 2018
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Ulrich Brinkmann, Alexander Haas, Silke Metz, Juergen Michael Schanzer
  • Alkaline feed
    Patent number: 9845347
    Abstract: A method for cultivating a bacterial cell comprising the addition of an amino acid in an alkaline solution used for pH regulation. Also an aspect is a method for producing a polypeptide comprising the steps of a) providing a bacterial cell comprising a nucleic acid encoding the polypeptide, b) cultivating the provided cell, c) adjusting the pH value during the cultivating with a basic solution comprising an amino acid, d) recovering the polypeptide from the cell or the cultivation medium and thereby producing the polypeptide.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: December 19, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventor: Christian Schantz
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 9802920
    Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: October 31, 2017
    Assignees: Hoffman-La Roche Inc., Chugai Pharamceutical Co.
    Inventors: Romyr Dominique, Norman Kong, Yan Lou, Francisco Javier Lopez-Tapia, Sung-Sau So
  • Multiplexed chromatography-immunoassay method for the characterization of circulating immune complexes
    Patent number: 9797900
    Abstract: Thus, herein is reported a method for analyzing/characterizing circulating immune complexes (CICs) formed in vivo comprising a size-exclusion chromatography of a sample obtained from a mammal to which the drug had been administered at least once for determining the weight/size of the immune complexes, optionally a second non-SEC chromatography, and at least one immunoassay, whereby the immune complex is characterized by the correlation of the immune complex size and the immunoassay result/read-out. Also reported herein is the use of a method as reported herein for determining a correlation to altered pharmacokinetics, for determining loss or reduction of efficacy, for determining neutralization of natural counterparts of the drug, for determining immune and hypersensitivity reactions, including serum sickness/type III hypersensitivity reaction/immune complex-mediated disease.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: October 24, 2017
    Assignee: F. HOFFMAN-LA ROCHE AG
    Inventors: Uwe Dahl, Gregor Jordan, Roland Staack
  • Anti-HER3 antibodies binding to the beta-hairpin of HER3
    Patent number: 9783611
    Abstract: The invention relates to specific anti-HER3 antibodies, that bind to the beta-hairpin of HER3, their preparation and use as medicament.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: October 10, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventors: Birgit Bossenmaier, Richard Buick, Michael Gerg, Frank Kroner, Gerhard Niederfellner, Carmen Peess, Michael Schraeml
  • Composition and methods for treating intestinal hyperpermeability
    Patent number: 9757348
    Abstract: The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV/AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: September 12, 2017
    Assignee: Steven Hoffman
    Inventor: Steven Hoffman
  • Oxytocin receptor agonists for the treatment of CNS diseases
    Patent number: 9751870
    Abstract: The invention relates to the use of a compound of formula I wherein A1 is phenyl or a five or six membered hereroaryl group, containing 1, 2 or 3 heteroatoms, selected from N or S; R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen or cycloalkyl; A2 is phenyl; R2 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cyano, S-lower alkyl substituted by halogen, S(O)2-lower alkyl substituted by halogen; n is 1 or 2; or a pharmaceutically acceptable acid addition salt, or a racemic mixture or its corresponding enantiomer and/or optical isomers thereof, for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrome.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: September 5, 2017
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Caterina Bissantz, Christophe Grundschober, Matthias Nettekoven, Jean-Marc Plancher, Walter Vifian
  • Camelid single-domain antibody directed against amyloid beta and methods for producing conjugates thereof
    Patent number: 9738712
    Abstract: The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid ? and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid ? deposits.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: August 22, 2017
    Assignees: F. HOFFMAN-LA ROCHE AG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CRNS), INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Fresh air cooling device
    Patent number: 9714770
    Abstract: Embodiments of the invention provide an air conditioning unit and a ventilator. The ventilator has an impeller to draw outside air into an enclosure and cause air within the enclosure to be exhausted to the outside. The ventilator can be tied into the air conditioning unit's control system and act to supplement the cooling and ventilation needs of the space. Alternatively, the ventilator can have a separate integral control system. By having a separate control system, the ventilator can operate as a stand-alone device.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: July 25, 2017
    Assignee: Hoffman Enclosures, Inc.
    Inventors: Michael Steven Rasmussen, Jeffrey Alan Thibedeau
  • Thienopyrimidine compounds
    Patent number: 9701691
    Abstract: The present invention relates to the use of novel compounds of Formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: July 11, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventors: Shaoqing Chen, Johannes Cornelius Hermann, Nam T. Le, Matthew C. Lucas, Fernando Padilla
  • Compositions and uses thereof
    Patent number: 9663517
    Abstract: Provided are solid dispersions, solid molecular complexes, salts and crystalline polymorphs involving propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: May 30, 2017
    Assignees: Plexxikon Inc., Hoffman-La Roche Inc.
    Inventors: Dipen Desai, Ralph Diodone, Zenaida Go, Prabha N. Ibrahim, Raman Iyer, Hans-Juergen Mair, Harpreet K. Sandhu, Navnit H. Shah, Gary Visor, Nicole Wyttenbach, Stephan Lauper, Johannes Pudewell, Frank Wierschem
  • MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
    Patent number: 9657351
    Abstract: Use of at least an MDM2 gene panel, preferably a four gene MDM2 gene panel, as a biomarker for predicting the response to a MDM2 antagonist.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: May 23, 2017
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Hua Zhong, David Geho, Gong Chen, Gwen Nichols, Markus Dangl
  • Methods of treating autoimmune diseases by administering monoclonal antibodies against human IL-12
    Patent number: 9657097
    Abstract: The present invention relates to novel p75 heterodimer specific anti-human IL-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human IL-12 bioactivity than known heterodimer specific IL-12 monoclonal antibodies. The heterodimer specific antibodies recognize one or more epitopes of the human IL-12 p75 heterodimer, but do not bind to the p40 subunit alone. The heterodimer specific IL-12 antibodies neutralize rhesus monkey IL-12 bioactivity with a potency similar to their potency for neutralizing human IL-12 bioactivity making them useful IL-12 antagonists for in vivo studies in the rhesus monkey.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: May 23, 2017
    Assignee: Hoffman-LaRoche, Inc.
    Inventors: Maurice Kent Gately, David Howard Presky
  • Phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors
    Patent number: 9636339
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1 and n are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: May 2, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventors: Johannes Aebi, Kurt Amrein, Robert Britton, Benoit Hornsperger, Bernd Kuhn, Hans P. Maerki, Rainer E. Martin, Alexander V. Mayweg, Xuefei Tan
  • Nucleic acids encoding antibodies against human CSF-1R and uses thereof
    Patent number: 9617342
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: April 11, 2017
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • Air conditioner
    Patent number: D803365
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: November 21, 2017
    Assignee: Hoffman Enclosures, Inc.
    Inventors: Richard L. Raisanen, Douglas L. Neuenfeldt, Michael J. Koehler, Randal A. Schroeder, William J. Nepsha, Adam Pawlowski, Klaus Peter Bachmann, Paul H. Landgraf